Breast cancer (HR-positive/HER2-negative)
- Endocrine therapy is the systemic foundation
- Premenopausal status determines ovarian-suppression strategy
- CDK4/6 inhibitor is central in advanced disease
- Selected high-risk early disease also uses CDK4/6 therapy
- Genomic assays can help decide chemotherapy in early disease
- Resistance mutations can guide later targeted therapy
Use at a glance
- Endocrine therapy is the systemic foundation
Practical pearls
- Premenopausal status determines ovarian-suppression strategy
- CDK4/6 inhibitor is central in advanced disease
Choosing treatment
- Genomic assays can help decide chemotherapy in early disease
- Resistance mutations can guide later targeted therapy
Treatment selection
- Selected high-risk early disease also uses CDK4/6 therapy
Self-check
- What is the systemic foundation for HR-positive/HER2-negative breast cancer?
Endocrine therapy. - What helps decide chemotherapy in early HR-positive/HER2-negative breast cancer?
Genomic assays.
Drugs used for this (7)
All clinical uses · Open Breast cancer (HR-positive/HER2-negative) in the interactive console ↗